Citius Oncology, Inc.
CTOR
NASDAQ·Healthcare·Medical - Pharmaceuticals·Mkt cap $80.0M
$0.86
▲ +8.56%
P/E
-2.07
Mkt Cap
$80.0M
52-Wk Range
$0.49–$2.25
52-Week Range
$0.49 - $2.25
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 53.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Very high volatility (beta 3.5). Expect 3x market swings. Position size accordingly.
Growth
Strong growth ahead
Value
Deep value opportunity - significant discount to sector peers
Momentum
Strong
+10.3% over 3m
Quality
Strong
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CTOR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
AUG 14, 2026
Reported EPS of -$0.08 vs -$0.07 consensus (-14.3% surprise). Revenue of $1.5M vs $2.5M expected (-40.3%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-14.3%
Revenue trend · last 3Q
—
—
—
Q1 26
Q2 26
Q3 26
$3.9M
$1.7M
$1.5M
Margins · last 3Q
Gross
-48.1%
Profit
-597.4%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How CTOR stacks vs Medical - Pharmaceuticals
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.